Jason Letman
President and Chief Executive Officer
Replay available
ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call
ALX Oncology Holdings Inc. (NASDAQ: ALXO) Q2 2025 earnings conference call, held 2025-08-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Investor Relations
Head of Investor Relations
Alison Bratzel
Analyst, Piper Sandler
Lee Watic
Analyst, Cantor Fitzgerald
Roger Song
Analyst, Jefferies
Sam Slutsky
Analyst, LifeSci Capital
Arthur He
Analyst, HC Wainwright
Ting Lui
Analyst, UBS
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Alx Oncology Holdings Inc..
Replay transcript excerpt
WEBVTT 00:00:01.600 -- 00:00:06.968 Greetings and welcome to the AOX Syncology second quarter 2025 00:00:06.968 -- 00:00:10.353 financial results conference call and webcast. 00:00:10.353 -- 00:00:14.018 At this time, all participants are in a listen-only mode. 00:00:14.018 -- 00:00:18.024 A question and answer session will follow the formal presentation. 00:00:18.024 -- 00:00:22.971 If anyone requires operator assistance during the conference, please press star zero 00:00:22.971 -- 00:00:27.878 on your telephone keypad. As a reminder, this conference is being recorded. 00:00:27.878 -- 00:00:34.429 I would now like to turn the conference over to your host, Jason Letman, you may begin. 00:00:36.556 -- 00:00:41.623 Thanks, everyone, and welcome to our Q2 2025 00:00:41.623 -- 00:00:42.785 results. 00:00:42.785 -- 00:00:47.311 I appreciate everybody spending some time this afternoon with us and looking forward 00:00:47.311 -- 00:00:52.759 to this update. On slide two, before we start our presentation as housekeeping, here 00:00:52.759 -- 00:00:55.944 are our forward-looking statements for your review. 00:00:55.944 -- 00:01:00.578 So, in terms of slide three, this is the agenda and plan for today. 00:01:00.578 -- 00:01:04.803 We're going to be providing an update on our key accomplishments in the second quarter 00:01:04.803 -- 00:01:06.664 of 2025. 00:01:06.664 -- 00:01:11.570 Most notably, we are very excited to share with you new data from our analysis of our 00:01:11.570 -- 00:01:17.136 Aspen 6 trial that showed CD47 expression as a key predictive 00:01:17.136 -- 00:01:21.901 biomarker for increasing clinical response with the 4-percept. 00:01:21.901 -- 00:01:26.556 So our goals for today are most importantly to share this new data with you all, then 00:01:26.556 -- 00...